半胱天冬酶14的表达与乳腺癌患者的三阴性表型及癌症干细胞标志物表达相关。
Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.
作者信息
Handa Tadashi, Katayama Ayaka, Yokobori Takehiko, Yamane Arito, Horiguchi Jun, Kawabata-Iwakawa Reika, Rokudai Susumu, Bao Pinjie, Gombodorj Navchaa, Altan Bolag, Kaira Kyoichi, Asao Takayuki, Kuwano Hiroyuki, Nishiyama Masahiko, Oyama Tetsunari
机构信息
Department of Diagnostic Pathology, Gunma University, Graduate School of Medicine, Maebashi, Japan.
Research Program for Omics-Based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research (GIAR), Maebashi, Japan.
出版信息
J Surg Oncol. 2017 Nov;116(6):706-715. doi: 10.1002/jso.24705. Epub 2017 Jun 1.
BACKGROUND AND OBJECTIVES
The Caspase14 (CASP14) was reported that the low expression of CASP14 in ovarian cancer and colon cancer was associated with cancer progression, on the other hand, that the CASP14 expression in breast cancer was higher than that of non-cancerous tissues. The purpose of this study is to determine the clinical significance of CASP14 in breast cancer.
METHODS
We performed immunohistochemistry for CASP14, ER, PgR, HER2, Ki67, EGFR, CK5/6, CD44, CD24, ALDH1, claudins, and androgen receptor in 222 breast cancer patients including 55 TNBC cases, and evaluated the relationship of CASP14, above-mentioned markers, and prognosis. Using public microarray database of breast cancer, the prognostic value of CASP14 was calculated.
RESULTS
High CASP14 expression was significantly associated with TNBC subtype (P = 0.015), nuclear grade (P = 0.006), Ki67, EGFR (P < 0.001, P = 0.016), ALDH1, CD44 and CD24 (P < 0.001, P < 0.001, P = 0.001) in 222 breast cancer cases, and the high expression of claudin1 (P = 0.017), and androgen receptor (P = 0.002) in TNBC cases was related to the high CASP14. According to the public database, survival in the high CASP14 breast cancer patients was shorter than low CASP14 patients.
CONCLUSIONS
High CASP14 expression is a marker of breast cancer aggressiveness in association with proliferation, TNBC phenotype, and cancer stemness.
背景与目的
据报道，半胱天冬酶14（CASP14）在卵巢癌和结肠癌中的低表达与癌症进展相关，另一方面，其在乳腺癌中的表达高于非癌组织。本研究旨在确定CASP14在乳腺癌中的临床意义。
方法
我们对222例乳腺癌患者（包括55例三阴性乳腺癌病例）进行了CASP14、雌激素受体（ER）、孕激素受体（PgR）、人表皮生长因子受体2（HER2）、Ki67、表皮生长因子受体（EGFR）、细胞角蛋白5/6（CK5/6）、CD44、CD24、醛脱氢酶1（ALDH1）、闭合蛋白以及雄激素受体的免疫组化检测，并评估了CASP14与上述标志物及预后的关系。利用公开的乳腺癌微阵列数据库，计算了CASP14的预后价值。
结果
在222例乳腺癌病例中，CASP14高表达与三阴性乳腺癌亚型（P = 0.015）、核分级（P = 0.006）、Ki67、EGFR（P < 0.001，P = 0.016）、ALDH1、CD44和CD24（P < 0.001，P < 0.001，P = 0.001）显著相关，在三阴性乳腺癌病例中，闭合蛋白1高表达（P = 0.017）和雄激素受体高表达（P = 0.002）与CASP14高表达相关。根据公开数据库，CASP14高表达的乳腺癌患者生存期短于CASP14低表达患者。
结论
CASP14高表达是乳腺癌侵袭性的一个标志物，与增殖、三阴性乳腺癌表型和癌症干性相关。
Zotero 插件